B-Cell Lymphoma Screening: Lymphoclonal-12

B-Cell Lymphoma Screening: Lymphoclonal-12

Lymphoclonal™-12 is intended to be used as a screening for B-cell lymphoma within a variety of clinical samples when the pre-test probability is low or unknown. This is particularly useful in paucicellular specimens such as fine needle aspirate, core biopsy and cerebral spinal fluid (CSF) where limited sample is available. Other tissues including pleural and ascitic fluid, peripheral blood (PB) and bone marrow aspirate (BMA) are also applicable within the appropriate setting*.

Interrogation of CD5 and CD10 expression makes possible complete assessment of normal B-cell maturation, thereby providing better differentiation between normal and abnormal B-cells and the subclassification of B-cell lymphoma, in addition to defining surface light chain expression, whilst also providing a global assessment of other leukocyte populations.

lymph-12

Background:

Detection of phenotypically aberrant and clonal mature lymphocytes is the diagnostic hallmark of chronic lymphoproliferative disorders (CLPD). Clonogenic events lead to the expansion and accumulation of mature-appearing lymphocytes, which carry a proliferative and/or survival advantage over their normal counterparts.

Flow Cytometry is a powerful tool which provides rapid, quantitative and multiparametric analysis of heterogeneous cell populations on a cell-by-cell basis. Flow cytometry is performed on cells in liquid suspension that have been incubated with fluorescently-labeled antibodies directed against specific cellular proteins. The relative fluorescence intensity of the positive cells indicates the amount of
antibody bound to specific binding sites on the cells, and therefore provides a relative measure of antigen expression.

The Lymphoclonal-12 kit recognises by flow cytometry the antigens CD45, CD3, CD56, CD4, CD8, CD5, CD20, CD19, CD10, CD38, kappa and lambda light chains expressed by different lymphocyte subsets and plasma cells, and can therefore be used in the immunophenotypic characterisation studies of lymphocytes and plasma cells. These studies are widely applied in the characterisation and follow-up of different hematological malignancies (2-5).

Product Information:

Product Name: Lymphoclonal™-12
Product Code: CYT-LC12
Status: RUO
Size: 25 Tests

View the Product Information Sheet Here.
Lymphoclonal™ is also available to purchase as a 5 test sample.

The Lymphoclonal-12 Kit developed by Cytognos is available exclusively in the UK from Caltag Medsystems. If you would like further information about this product, please contact us and we will be happy to help.

References:

1. Van Dongen JJM, Lhermitte L, Böttcher S, Almeida J, van der Velden VHJ, Flores-Montero J, et al. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia, 2012, Sep;26(9):1908-75. doi:10.1038/leu.2012.120. Epub 2012 May 3.

2. Sanchez ML, Almeida J, Vidriales B, López-Berges MC, et al. Incidence of phenotipic aberrations in a serie of 467 patients with B chronic lymphoprolipherative disorders: basis for the design of specific four color stainnings to be used for minimal residual disease investigation. Leukemia 2002 Aug; 16/8): 1460-1469.

3. Davis BH, Holden JT, Bene MC, Borowitz MJ, Braylan RC, Cornfield D, Gorczyca W, Lee R, Maiese R, Orfao A, Wells D, Wood BL, Stetler-Stevenson M. 2006-Bethesda. International Consensus recommendations on the flow cytometric immunophenotypic analysis of hematolymphoid neoplasia: Medical indications. Cytometry Part B 72B:S5–S13 (2007).

4. Ruiz-Argüelles A, Rivadeneyra-Espinoza L, Duque RE, Orfao A, Latin American Consensus Conference. Report on the second Latin American consensus conference for flow cytometric immunophenotyping of hematological malignancies. Cytometry Part B 70B:39–44 (2006).

5. Stetler-Stevenson M. H43-A2 Clinical Flow Cytometric Analysis of Neoplastic Hematolymphoid Cells; Approved Guideline, 2nd ed. Clinical and Laboratory Standards Institute: Wayne, PA; (2007).

6. Kalina T, Flores-Montero J, van der Velden VHJ, Martin-Ayuso M, Böttcher S, Ritgen M, et al. EuroFlow standardization of flow cytometry instrument settings and immunophenotyping protocols. Leukemia, 2012 Sep; 26(9):1986-2010. doi:10.1038/leu.2012.122.

7. Protection of Laboratory Workers from occupationally acquired infections. Second edition; approved guideline (2001). Villanova PA: National Committee for Clinical Laboratory Standards; Document M29-A2.

8. Procedures for the collection of diagnostic blood specimens by venipuncture- approved standard; Fifth edition (2003). Wayne PA: National Committee for Clinical Laboratory Standards; Document H3-A5.

9. Clinical applications of flow cytometry: Quality assurance and immunophenotyping of lymphocytes; approved guideline (1998). Wayne PA: National Committee for Clinical Laboratory Standards; Document H42-A.

10. Fukushima PI, Thi Nguyen PK, O`Grady P, Stetler-Stevenson M. Flow cytometric analysis of kappa and lambda light chain expression in evaluation of specimens for B-cell neoplasia. Cytometry (Communications in clinical Cytometry) 26: 243-252 (1996).

11. Braylan RC, Orfao A, Borowitz MJ, Davis BH. Optimal number of reagents required to evaluate hematolymphoid neoplasias: results of an international consensus meeting. Cytometry 46: 23-7 (2001)

B-Cell Lymphoma Screening: Lymphoclonal-12